C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
NCT ID: NCT01397864
Last Updated: 2025-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
181 participants
OBSERVATIONAL
2011-07-31
2024-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patient Registry to Evaluate the Real-world Safety of Ruconest®
NCT03697187
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
NCT00262301
C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
NCT01005888
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
NCT00462709
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks
NCT00438815
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hereditary Angioedema
rhC1INH or pdC1INH
C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rhC1INH or pdC1INH
C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must give written informed consent
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pharming Technologies B.V.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anurag Relan, MD
Role: STUDY_DIRECTOR
Pharming Technologies BV
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UMHAT Alexandrovska EAD
Sofia, , Bulgaria
KBC Split
Split, , Croatia
General Hospital Sibenik
Šibenik, , Croatia
CHC Sestre milosrdnice
Zagreb, , Croatia
Faculty Hospital by St. Anna Brno
Brno, , Czechia
Hospital A Michallon, CHU Grenoble
La Tronche, , France
Charite Universitatsmedizin Berlin
Berlin, , Germany
Semmelweis University, 3rd Department of Internal Medicine
Budapest, , Hungary
Ospedale Luigi Sacco
Milan, , Italy
PHI University Clinic of Dermatology
Skopje, , North Macedonia
Alesund Hospital
Ålesund, , Norway
Stavanger University Hospital
Stavanger, , Norway
University Hospital Krakow
Krakow, , Poland
Bratislava University Hospital
Bratislava, , Slovakia
University Hospital Martin
Martin, , Slovakia
University Clinic Golnik
Golnik, , Slovenia
Ryhof County Hospital
Jönköping, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C1 1412
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.